Literature DB >> 21296777

Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation.

Leif Friberg1, Mårten Rosenqvist.   

Abstract

AIMS: Cardiovascular (CV)-related hospitalization has been used as a surrogate endpoint for mortality in recent treatment studies on atrial fibrillation (AF), but our understanding of the relationship between CV-related hospitalization and death is incomplete. We aimed to investigate whether CV-related hospitalization is an independent risk factor and suitable as a surrogate endpoint for death in clinical studies of patients with AF. METHOD AND
RESULTS: All 2912 patients with a diagnosis of AF in 2002 at one of Sweden's largest hospitals were studied for 6.5 years using information about medication from the local medical records. In a sub-study of the last 2.5 years of the study period, we used detailed information about medication from the new National Prescription Register. Information about diagnoses, hospitalizations, and deaths was obtained from national registries. Patients who were re-admitted to hospital with a CV diagnosis within the first 3 months had higher mortality than those who were not (15.6 vs. 9.3 deaths per 100 patient-years at risk, P < 0.0001). Those who spent >2% of their time-at-risk in hospital with a CV diagnosis had higher mortality than those who had spent less time in hospital (36.0 vs. 8.2 deaths per 100 patient years, P < 0.0001). After adjustment for co-factors, mortality was still higher for patients who had been re-hospitalized for CV disease within 3 months than for those who had not [hazard ratio (HR) = 1.36; 95% confidence interval (CI) = 1.18-1.57]. When analyses were performed on patients who had survived for 3 years since inclusion, and with the use of detailed information about the exposure to medication, the association between CV-related hospitalization and death was highly significant (HR 2.69, CI 1.96-3.68). These results were virtually unchanged after propensity score matching, which was done in order to adjust further for residual unidentified confounding.
CONCLUSION: CV-related hospitalization is a marker for patients who are at increased risk of death, and may be used as a valid surrogate endpoint in studies of AF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296777     DOI: 10.1093/europace/eur001

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  7 in total

1.  Rate control in atrial fibrillation, insight into the RACE II study.

Authors:  H F Groenveld; H J G M Crijns; J G P Tijssen; M Alings; H L Hillege; Y S Tuininga; M P Van den Berg; D J Van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2013-04       Impact factor: 2.380

2.  Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.

Authors:  Nancy M Allen LaPointe; David Dai; Laine Thomas; Jonathan P Piccini; Eric D Peterson; Sana M Al-Khatib
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-03-31

3.  Syndecan-4 shedding is involved in the oxidative stress and inflammatory responses in left atrial tissue with valvular atrial fibrillation.

Authors:  Han Wu; Qing Zhou; Jun Xie; Guan-Nan Li; Qin-Hua Chen; Li-Na Kang; Biao Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension.

Authors:  Marcel Halbach; David Grothaus; Fabian Hoffmann; Navid Madershahian; Kathrin Kuhr; Hannes Reuter
Journal:  Clin Auton Res       Date:  2020-02-12       Impact factor: 4.435

5.  Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.

Authors:  Christian Torp-Pedersen; Harry J G M Crijns; Christophe Gaudin; Richard L Page; Stuart J Connolly; Stefan H Hohnloser
Journal:  Europace       Date:  2011-05-15       Impact factor: 5.214

Review 6.  How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?

Authors:  Rajiv Sankaranarayanan; Graeme Kirkwood; Rajaverma Visweswariah; David J Fox
Journal:  Curr Cardiol Rev       Date:  2015

7.  Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study.

Authors:  Christine Benn Christiansen; Jonas Bjerring Olesen; Gunnar Gislason; Morten Lock-Hansen; Christian Torp-Pedersen
Journal:  BMJ Open       Date:  2013-01-24       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.